Safety of intravenous injection of iron saccharate in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 11, Issue 9, 1996, Pages 1797-1802

  Sunder Plassmann, G ^a   Horl W H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Erythropoietin; Ferritin; Haemodialysis; Iron saccharate; Transferrin saturation

Indexed keywords

FERRITIN; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON BLOOD LEVEL; IRON METABOLISM; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SUPPLEMENTATION; TRANSFERRIN BLOOD LEVEL;

EID: 0029798218     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027671     Document Type: Article

References (15)

1. Edwards MS, Pegrum GD, Curtis JR. Iron therapy in patients on maintenance haemodialysis. Lancet 1970; 2: 491-493
2. Crockett RE, Baillod RA, Lee BN, Moorhead JF, Stevenson CM, Varghese Z, Shaldon S. Maintenance of fifty patients on intermittent haemodialysis without blood transfusion. Proc EDTA 1967; 4: 17-22
3. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87: 710-713
4. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178
5. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
6. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076
7. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 1996; 11: 319-322
8. Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G. How to diagnose and correct iron deficiency during rHuEpo therapy a consensus report. Nephrol Dial Transplant 1996; 11: 246-250
9. Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong GMTh. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824
10. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57: 175-182
11. Macdougall IC, Tucker B, Thompson J, Baker LRI. Raine AEG. A randomised controlled study of iron supplementation in patients treated with erythropoietin. J Am Soc Nephrol 1993; 4: 428 (abstract)
12. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-1731
13. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneim-Forsch/Drug Res 1992; 42: 1439-1452
14. Evers J. Parenteral iron during hemodialysis. Nephron 1993; 64: 490 (letter)
15. Hatton RC, Portales IT, Finlay A, Ross EA. Removal of iron dextran by hemodialysis: an in vitro study. Am J Kidney Dis 1995; 26: 327-330